# US 10,946,104 B2 · Aberrant cell-restricted immunoglobulins provided with a toxic moiety > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,946,104 B2 - Document ID: US10946104B2 - Status: Granted - Kind: B2 - Application number: 14/372,094 - Filed: 2013-01-11 - Published: 2015-02-26 - Granted: 2021-03-16 - Earliest claimed: 2012-01-13 - Assignees: Apo-Tb.V. - Applicants: Apo-T B.V. - Inventors: Johan Renes; Paul Steverink; Ralph Alexander Willemsen - Web page: https://patentgrep.com/patent/US10946104B2 ## CPC - A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon} - A61K 47/6809: {Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin} - A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant} - A61K 47/6851: {the antibody targeting a determinant of a tumour cell} - A61K 47/6883: {Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy} - A61P 35/00: Antineoplastic agents - C07K 16/084: Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus - C07K 16/085: Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus - C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules} - C07K 16/2884: {against CD44} - C07K 16/30: from tumour cells - C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate} - C07K 16/3092: {against tumour-associated mucins} - C07K 16/32: against translation products of oncogenes - C07K 16/40: against enzymes - A61K 2039/505: {comprising antibodies} - C07K 2317/32: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody® - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an MHC-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes. The provided immunoglobulins provided with a toxic moiety are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases. ## Claims ### Claim 1 An immunoglobulin conjugated to a toxic moiety comprising at least an immunoglobulin region that specifically binds to an MHC-I-MAGE peptide complex, wherein the immunoglobulin region comprises a Vh domain comprising SEQ ID NO: 1; wherein the MAGE peptide of the MHC-I-MAGE peptide complex is derived from intracellular MAGE associated with aberrant cells; and wherein the MAGE peptide is a multi-MAGE epitope. ### Claim 2 (depends on 1) The immunoglobulin conjugated to a toxic moiety according to claim 1, wherein the immunoglobulin region further comprises a Vl. ### Claim 3 (depends on 1) The immunoglobulin conjugated to a toxic moiety of claim 1, wherein the MHC-I-MAGE peptide complex is specific for aberrant cells. ### Claim 4 (depends on 1) A pharmaceutical composition comprising: the immunoglobulin conjugated to a toxic moiety of claim 1, and suitable diluents and/or excipients. ### Claim 5 (depends on 1) A method of treating a host suffering from a disease associated with aberrant cells, the method comprising: administering the immunoglobulin conjugated to a toxic moiety of claim 1 to the host, for the treatment of the host suffering from a disease associated with aberrant cells. ### Claim 6 (depends on 5) The method according to claim 5, wherein the toxic moiety is internalized into an aberrant cell of the host. ### Claim 7 (depends on 1) A method of treating a subject determined to be suffering from cancer, the method comprising: administering the immunoglobulin conjugated to a toxic moiety of claim 1 to the host to treat cancer. ### Claim 8 (depends on 7) The method according to claim 7, wherein at least the toxic moiety is internalized into an aberrant cell of the subject. ### Claim 9 (depends on 3) The immunoglobulin conjugated to a toxic moiety of claim 3, wherein the MAGE is MAGE-A. ### Claim 10 (depends on 1) The immunoglobulin conjugated to a toxic moiety of claim 1, wherein the toxic moiety is a fusion protein fused to the immunoglobulin at the DNA level through a linking sequence. ### Claim 11 (depends on 1) The immunoglobulin conjugated to a toxic moiety of claim 1, wherein the MHC-I-MAGE peptide complex is upregulated on aberrant cells.